SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kai Bao, Foxiao Qiao, Long Liang, Hanbing Li, Huajun Zhu, Weige Zhang, Yingliang Wu, Synthesis and antiproliferative activity of novel erythromycin derivatives, MedChemComm, 2010, 1, 4, 294

    CrossRef

  2. 2
    Erik Hankø, Steve Tommarello, Jon F Watchko, Thor W R Hansen, Administration of Drugs Known to Inhibit P-Glycoprotein Increases Brain Bilirubin and Alters the Regional Distribution of Bilirubin in Rat Brain, Pediatric Research, 2003, 54, 4, 441

    CrossRef

  3. 3
    Lars Möllgård, Eva Hellberg, Adam Smolowicz, Christer Paul, Ulf Tidefelt, Interactions Between P-Glycoprotein and Drugs Used in the Supportive Care of Acute Myeloid Leukemia Patients, Leukemia & Lymphoma, 2001, 42, 1-2, 177

    CrossRef

  4. 4
    U. Stein, W. Walther, C. M. Laurencot, R. H. Shoemaker, G. L. Scheffer, R. J. Scheper, Tumor Necrosis factor-  and Expression of the Multidrug Resistance-Associated Genes LRP and MRP, JNCI Journal of the National Cancer Institute, 1997, 89, 11, 807

    CrossRef

  5. 5
    Eva Hofsli, Anders Waage, Effect of pyridoxine on tumor necrosis factor activitiesin vitro, Biotherapy, 1992, 5, 4, 285

    CrossRef

  6. 6
    Susan C. Wright, Albert W. Tam, Poornima Kumar, Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance, Cancer Immunology Immunotherapy, 1992, 34, 6, 399

    CrossRef

  7. 7
    Gerald Zernig, Widening potential for Ca2+ antagonists: non-L-type Ca2+ channel interaction, Trends in Pharmacological Sciences, 1990, 11, 1, 38

    CrossRef

  8. 8
    Eva Hofsli, Jon Nissen-meyer, Reversal of drug resistance by erythromycin: Erythromycin increases the accumulation of actinomycin d and doxorubicin in multidrug-resistant cells, International Journal of Cancer, 1989, 44, 1